Business Context and Reporting Period
This Form 8-K is a current report filed by Synta Pharmaceuticals Corp. on November 18, 2013. The filing reports the closing of a previously announced public offering of common stock. Note: The request metadata references "Madrigal Pharmaceuticals, Inc.," but the source text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial event reported is the capital raise:
- Shares Issued: 16,100,000 shares of common stock.
- Over-Allotment: Includes 2,100,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares.
- Offering Price/Total Proceeds: The filing text does not provide a clear value for the price per share or total gross proceeds.
Material Changes
The material change reported is the increase in outstanding common stock and the corresponding increase in cash liquidity resulting from the closing of the public offering on November 18, 2013.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or contingencies beyond the announcement of the offering closing. A press release dated November 18, 2013, is filed as Exhibit 99.1 and incorporated by reference, but its specific content is not detailed in the provided text.
Investor Verification Checklist
- Verify the offering price per share and total gross proceeds by reviewing Exhibit 99.1 (Press Release).
- Confirm the use of proceeds as detailed in the accompanying press release.
- Review the updated capitalization table to reflect the issuance of 16,100,000 new shares.
- Check for any dilution impact on existing shareholders.